8-K filing — Kenvue Inc. (KVUE)
Filed: 2026-11-04 AccNo: 0001104659-26-122777 Size: 199 KB Item 3.03: Material Modifications to Rights of Security Holders Item 9.01: Financial Statements and Exhibits
Stocks · News reference
UBS has updated its price target for Kenvue Inc. while maintaining a Neutral rating.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-11-04 AccNo: 0001104659-26-122777 Size: 199 KB Item 3.03: Material Modifications to Rights of Security Holders Item 9.01: Financial Statements and Exhibits
Kimberly-Clark Corporation announced the expiration and final results of its exchange offers and consent solicitations regarding Kenvue Notes.
Kimberly-Clark completed its $48.7 billion acquisition of Kenvue on Monday, creating a consumer goods and healthcare powerhouse with 10 billion-dollar brands. The deal was funded through senior notes and the sale of a 51% stake in its paper business to Suzano. The company expects $2.1 billion in annual synergies within three years and aims to maintain its 54-year Dividend King status through incremental raises, though share buybacks have been suspended.
Kimberly-Clark has finalized its acquisition of Kenvue, with Kenvue shareholders receiving a combination of cash and stock as part of the transaction.
Kenvue Inc. is set to be removed from the S&P 500 index, with Okta designated as its replacement.
Kenvue Inc. is expected to be delisted from the New York Stock Exchange as its $40 billion acquisition by Kimberly-Clark nears completion.